Stay updated with breaking news from Tumor Drivers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA (olaparib), IMFINZI(durvalumab), chemotherapy and bevacizumab demonstrated
Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® , IMFINZI® , chemotherapy and bevacizumab demonstrated a... | June 3, 2023
26.05.2023 - Positive high-level results from the DUO-E Phase III trial showed IMFINZI (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a ...
Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities
In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy. In line with uptake observed in prior studies and clinical practice, younger patients (